Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis
Status:
Completed
Trial end date:
2020-12-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to prove the superiority of a 48-weeks treatment with budesonide
orodispersible tablets versus placebo for the maintenance of clinico-pathological remission
in patients with eosinophilic esophagitis.